UroToday3d
Update on PSMA-based Prostate Cancer Imaging - Beyond the Abstract
The advent of PSMA-based PET imaging has brought a transformative shift in the personalized management of prostate cancer (PCa), with increasing routine clinical utilization across different stages of ...
UroToday3d
Final Analysis of Post-Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan.
Avelumab, an anti-programmed death ligand 1 antibody, was approved in combination with axitinib for curatively unresectable or metastatic renal cell carcinoma (RCC) in Japan in December 2019. Because ...
UroToday3d
Construction and evaluation of a prognostic model for metabolism-related genes in kidney renal clear cell carcinoma using TCGA database.
To investigate the expression of metabolism-related genes (MRGs) in kidney renal clear cell carcinoma (KIRC) and their association with patient prognosis, and to identify potential targets for ...
UroToday3d
Clinical significance of stratifying prostate cancer patients through specific circulating genes.
Patient stratification remains a challenge for optimal treatment of prostate cancer (PCa). This clinical heterogeneity implies intra-tumoural heterogeneity, with different prostate epithelial cell ...
UroToday3d
A New AI Model for Grading Non-Muscle Invasive Bladder Cancer - Expert Commentary
Accurate grading and staging of non-muscle invasive bladder cancer (NMIBC) is critical for prognosis and treatment selection. The advent of digital pathology and artificial intelligence (AI) has ...
UroToday3d
Treatment algorithm following first-line therapy failure in metastatic prostate cancer.
This article provides a comprehensive overview of the current treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) following the failure of first-line therapy.
UroToday3d
AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses.
Non-muscle-invasive Bladder Cancer (NMIBC) is notorious for its high recurrence rate of 70-80%, imposing a significant human burden and making it one of the costliest cancers to manage. Current ...
UroToday3d
Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-DRE Urine.
The 18-gene MyProstateScore 2.0 (MPS2) test was previously validated for detection of Grade Group≥2 (GG≥2) prostate cancer using post-digital rectal examination (DRE) urine. To improve ease of testing ...
UroToday3d
The Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer Care.
The Co-IMPACT consortium addresses knowledge gaps in prostate-specific membrane antigen positron emission tomography-guided radiotherapy for prostate cancer by establishing a global database (46 ...
UroToday3d
Impact of race-based calculations of eGFR on the management of muscle invasive bladder cancer.
The estimated glomerular filtration rate (eGFR) has historically been calculated with a race-coefficient multiplier (RCM); however, the RCM has been broadly criticized as inaccurate and a potential ...
UroToday3d
Bridging the gap: Evaluating ChatGPT-generated, personalized, patient-centered prostate biopsy reports.
The highly specialized language used in prostate biopsy pathology reports coupled with low rates of health literacy leave some patients unable to comprehend their medical information. Patients' use of ...
UroToday3d
Precise grading of non-muscle invasive bladder cancer with multi-scale pyramidal CNN.
The grading of non-muscle invasive bladder cancer (NMIBC) continues to face challenges due to subjective interpretations, which affect the assessment of its severity. To address this challenge, we are ...